Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
GlaxoSmithKline
Description:
Cancer of the uterine corpus, also called endometrial cancer (EC),
is the most common cancer of the female genital tract, with an
estimated 65,950 new cases diagnosed and 12,550 deaths annually in
the United States. The mortality rate has increased approximately 1%
each year from 2015 to 2019, an increase which may be related to a
higher rate of advanced-stage cancers, high-risk histologies, and
patients being diagnosed at an older age. There are significant
disparities between White and Black women regarding rates of
early-stage diagnosis (75% vs 62%) and 5-year relative survival (84%
vs 63%). When patients are diagnosed with distant-stage disease,
5-year relative survival rates plummet to 18% for all races. Early
identification of high-risk patients and personalized treatment
approaches for this complex, multifaceted disease are needed to
improve outcomes. Fortunately for patients with endometrial cancer,
new and emerging combination regimens, including immunotherapy and
targeted therapy combinations, have been approved in recent years,
giving managed care professionals and clinicians more options for
treating this patient population. With so many new therapies
entering the treatment paradigm, knowledge gaps have been created,
making it imperative that managed care physician medical directors,
oncologists, pharmacists, payers, nurses and other healthcare
professionals who manage EC patient populations have a solid
understanding of these options to optimize both costs and patient
outcomes in their therapeutic application, for optimized clinical
and economic outcomes.
Upon completion of this
activity, participants will be able to:
-
Assess the clinical and economic
burden of endometrial cancer (EC) in terms of relative survival,
mortality, drug utilization, adverse event management, and
hospitalizations
-
Explore the prognosis of advanced
endometrial cancer and the significance of biomarkers in
determining appropriate therapy
-
Analyze recent clinical data on the
efficacy, safety and mechanisms of action of novel therapies,
including PD-1 inhibitors, in the management of endometrial
cancer
-
Review the guideline-recommended
role of immune-based therapies in the management of endometrial
cancer
-
Investigate health equity issues
affecting patients with endometrial cancer and the potential
impact of disparities on clinical outcomes
-
Discuss access to care, cost of
care, and cost-effectiveness of immune checkpoint inhibitors in
the treatment of endometrial cancer
|
Faculty: |
Shannon N. Westin, MD,
MPH
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Dept. of Gynecologic Oncology and Reproductive Medicine
UT MD Anderson Cancer Center |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Westin has served as a consultant for AstraZeneca,
Caris, Clovis Oncology, Eisai, EQRX, GSK, ImmunoGen,
Lilly, Merck, Mereo, Mersana, NGM Bio, Nuvectis, Roche/Genentech,
SeaGen, Verastem, Vincerx, and Zentalis. She has
received grant/research support from AstraZeneca,
AvengeBio, Bayer, Bio-Path, Clovis Oncology, GSK, Mereo,
Novartis, Roche/Genentech, and Zentalis. Her
presentation has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by an educational grant from
GlaxoSmithKline
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |